Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Inmaculada Rioja

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Journal of Medicinal Chemistry|July 24, 2020
The Optimization of a Novel, Weak Bromo and Extra Terminal Domain (BET) Bromodomain Fragment Ligand to a Potent and Selective Second Bromodomain (BD2) InhibitorJonathan T Seal, Stephen J Atkinson, Helen Aylott, et al.
Journal of Crohn'S & Colitis|October 11, 2021
Carboxylesterase-1 Assisted Targeting of HDAC Inhibitors to Mononuclear Myeloid Cells in Inflammatory Bowel DiseaseAhmed M I Elfiky, Mohammed Ghiboub, Andrew Y F Li Yim, et al.
Journal of Medicinal Chemistry|July 13, 2021
Fragment-based Scaffold Hopping: Identification of Potent, Selective, and Highly Soluble Bromo and Extra Terminal Domain (BET) Second Bromodomain (BD2) InhibitorsJonathan T Seal, Stephen J Atkinson, Paul Bamborough, et al.
The Journal of Clinical Investigation|April 15, 2022
Combined noncanonical NF-κB agonism and targeted BET bromodomain inhibition reverse HIV latency ex vivoShane D Falcinelli, Jackson J Peterson, Anne-Marie W Turner, et al.
Journal of Medicinal Chemistry|November 15, 2022
Identification and Optimization of a Ligand-Efficient Benzoazepinone Bromodomain and Extra Terminal (BET) Family Acetyl-Lysine Mimetic into the Oral Candidate Quality Molecule I-BET432Philip G Humphreys, Niall A Anderson, Paul Bamborough, et al.
Science (New York, N.Y.)|March 21, 2020
Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammationOmer Gilan, Inmaculada Rioja, Kathy Knezevic, et al.
Journal of Medicinal Chemistry|January 7, 2022
Design, Synthesis, and Characterization of I-BET567, a Pan-Bromodomain and Extra Terminal (BET) Bromodomain Oral CandidatePhilip G Humphreys, Stephen J Atkinson, Paul Bamborough, et al.
Journal of Medicinal Chemistry|June 12, 2024
Structure- and Property-Based Optimization of Efficient Pan-Bromodomain and Extra Terminal Inhibitors to Identify Oral and Intravenous Candidate I-BET787David J Hirst, Paul Bamborough, Niam Al-Mahdi, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Journal of Medicinal Chemistry|July 24, 2020
The Optimization of a Novel, Weak Bromo and Extra Terminal Domain (BET) Bromodomain Fragment Ligand to a Potent and Selective Second Bromodomain (BD2) InhibitorJonathan T Seal, Stephen J Atkinson, Helen Aylott, et al.
Journal of Crohn'S & Colitis|October 11, 2021
Carboxylesterase-1 Assisted Targeting of HDAC Inhibitors to Mononuclear Myeloid Cells in Inflammatory Bowel DiseaseAhmed M I Elfiky, Mohammed Ghiboub, Andrew Y F Li Yim, et al.
Journal of Medicinal Chemistry|July 13, 2021
Fragment-based Scaffold Hopping: Identification of Potent, Selective, and Highly Soluble Bromo and Extra Terminal Domain (BET) Second Bromodomain (BD2) InhibitorsJonathan T Seal, Stephen J Atkinson, Paul Bamborough, et al.
The Journal of Clinical Investigation|April 15, 2022
Combined noncanonical NF-κB agonism and targeted BET bromodomain inhibition reverse HIV latency ex vivoShane D Falcinelli, Jackson J Peterson, Anne-Marie W Turner, et al.
Journal of Medicinal Chemistry|November 15, 2022
Identification and Optimization of a Ligand-Efficient Benzoazepinone Bromodomain and Extra Terminal (BET) Family Acetyl-Lysine Mimetic into the Oral Candidate Quality Molecule I-BET432Philip G Humphreys, Niall A Anderson, Paul Bamborough, et al.
Science (New York, N.Y.)|March 21, 2020
Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammationOmer Gilan, Inmaculada Rioja, Kathy Knezevic, et al.
Journal of Medicinal Chemistry|January 7, 2022
Design, Synthesis, and Characterization of I-BET567, a Pan-Bromodomain and Extra Terminal (BET) Bromodomain Oral CandidatePhilip G Humphreys, Stephen J Atkinson, Paul Bamborough, et al.
Journal of Medicinal Chemistry|June 12, 2024
Structure- and Property-Based Optimization of Efficient Pan-Bromodomain and Extra Terminal Inhibitors to Identify Oral and Intravenous Candidate I-BET787David J Hirst, Paul Bamborough, Niam Al-Mahdi, et al.
Pageof 5